{"product_id":"aplt-vrio-analysis","title":"Applied Therapeutics, Inc. (APLT): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs Applied Therapeutics, Inc. (APLT) truly positioned for long-term dominance, or are its current successes built on fragile foundations? We cut straight to the core of its competitive edge by dissecting its resources through the rigorous VRIO framework - Value, Rarity, Inimitability, and Organization. Uncover the distilled summary of our findings in \u0026amp;O4\u0026amp; below, and see exactly what makes Applied Therapeutics, Inc. (APLT) sustainably superior (or where it needs to adapt) before you read the full analysis.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eApplied Therapeutics, Inc. (APLT) - VRIO Analysis: \u003cstrong\u003e1. Govorestat Clinical Data for CMT-SORD Deficiency\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eYou're looking at the core asset for Applied Therapeutics, Inc. (APLT): Govorestat for CMT-SORD deficiency. Honestly, this is the make-or-break story right now, hinging entirely on regulatory success given the high unmet need.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Potential to Address Unmet Need\u003c\/h3\u003e\n\u003cp\u003eGovorestat shows clear potential because CMT-SORD is a rare, debilitating disease with zero approved treatments right now. The Phase III INSPIRE trial data, including 24-month results presented at PNS 2025, demonstrated statistically significant lowering of blood sorbitol levels (p \u0026lt; 0.001) and sustained improvements in the patient-reported CMT-Health Index (CMT-HI). MRI data also suggested a slowing of disease progression at 24 months. What this estimate hides, though, is that the primary endpoint, the 10-meter walk-run test, was not statistically significant (p=0.457) at 12 months.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math on the company's current state as of late 2025:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash and cash equivalents: \u003cstrong\u003e$11.9 million\u003c\/strong\u003e (as of Sept 30, 2025).\u003c\/li\u003e\n\u003cli\u003eQ3 2025 R\u0026amp;D Expenses: \u003cstrong\u003e$9.6 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe value proposition is clear: first-to-market for a fatal disease.\u003c\/p\u003e\n\n\u003ch3\u003eRarity and Imitability\u003c\/h3\u003e\n\u003cp\u003eThe rarity comes from the specific mechanism - a CNS-penetrant Aldose Reductase Inhibitor (ARI) targeting this SORD pathway - and the proprietary data package. Replicating the full 24-month INSPIRE trial data package would take years and massive capital outlay, making it highly inimitable in the near term. The mechanism is unique to CMT-SORD, which is caused by SORD gene mutations leading to toxic sorbitol accumulation.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization and Competitive Advantage\u003c\/h3\u003e\n\u003cp\u003eApplied Therapeutics, Inc. is actively organized around this asset, having completed a meeting with the FDA in the third quarter of 2025 to discuss the potential New Drug Application (NDA) submission strategy. They are awaiting the official meeting minutes to determine the definitive path forward. If they successfully navigate regulatory approval based on this proprietary data, the competitive advantage is \u003cstrong\u003esustained\u003c\/strong\u003e. Still, the current status is one of high potential contingent on FDA feedback.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Dimension\u003c\/th\u003e\n\u003cth\u003eAssessment for Govorestat (CMT-SORD)\u003c\/th\u003e\n\u003cth\u003eImplication\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eYes. Addresses fatal\/debilitating rare disease with no current drugs; shows biomarker and functional improvement.\u003c\/td\u003e\n\u003ctd\u003eCompetitive Parity to Potential Advantage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eYes. Late-stage, CNS-penetrant ARI for this specific indication is rare.\u003c\/td\u003e\n\u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInimitability\u003c\/td\u003e\n\u003ctd\u003eHigh. Replicating the full 24-month Phase 3 INSPIRE trial data package is difficult and capital-intensive.\u003c\/td\u003e\n\u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eActive engagement with FDA on NDA strategy, awaiting Q3 2025 meeting minutes for next steps.\u003c\/td\u003e\n\u003ctd\u003ePotential for Sustained Advantage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe current competitive advantage is \u003cstrong\u003etemporary\u003c\/strong\u003e, but the path to \u003cstrong\u003esustained\u003c\/strong\u003e advantage is clear: secure the NDA approval. Finance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eApplied Therapeutics, Inc. (APLT) - VRIO Analysis: \u003cstrong\u003e2. Proprietary Structure-Based Drug Design Platform\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eThe platform enables the development of novel drug candidates against validated molecular targets in rare diseases. The lead drug candidate, govorestat, is a novel central nervous system (CNS) penetrant Aldose Reductase Inhibitor (ARI) developed from this approach.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Allows for the functional design of new compounds with improved binding affinity and specificity for targets like Aldose Reductase.\u003c\/p\u003e\n\u003cp\u003eThe platform has yielded a franchise targeting CNS rare metabolic diseases, including:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eClassic Galactosemia\u003c\/li\u003e\n\u003cli\u003eCharcot-Marie-Tooth Sorbitol Dehydrogenase Deficiency (CMT-SORD)\u003c\/li\u003e\n\u003cli\u003ePhosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; many biotechs have platforms, but this one has yielded a CNS-penetrant ARI franchise.\u003c\/p\u003e\n\u003cp\u003eThe platform's output includes govorestat, which has progressed through multiple clinical trials for these indications. The company's lead drug candidate is an ARI for CNS rare metabolic diseases.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Temporary; the underlying science is known, but the specific compound library and optimization know-how are harder to copy.\u003c\/p\u003e\n\u003cp\u003eThe platform's development history includes eight years under founding leadership, during which multiple successful clinical trials were completed.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The leadership team has experience in drug discovery, which helps exploit this platform.\u003c\/p\u003e\n\u003cp\u003eRecent leadership includes Executive Chairman John H. Johnson, noted for having 40 years of transformational leadership experience at global healthcare organizations. The company's financial structure reflects ongoing investment in R\u0026amp;D related to these programs.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlatform Output\/Focus\u003c\/td\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003ePeriod\/Date\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eARI Franchise Indications\u003c\/td\u003e\n\u003ctd\u003eCNS Rare Metabolic Diseases Addressed\u003c\/td\u003e\n\u003ctd\u003e3 (Classic Galactosemia, CMT-SORD, PMM2-CDG)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Resource\u003c\/td\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$11.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlatform Investment (R\u0026amp;D)\u003c\/td\u003e\n\u003ctd\u003eResearch and Development Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$9.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eThree months ended September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlatform Overhead (G\u0026amp;A)\u003c\/td\u003e\n\u003ctd\u003eGeneral and Administrative Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eThree months ended September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary, as platform technology is often subject to rapid obsolescence or imitation.\u003c\/p\u003e\n\u003cp\u003eThe company has reported R\u0026amp;D expenses of $9.6 million for the three months ended September 30, 2025, compared to $14.8 million for the same period in 2024. Cash reserves stood at $11.9 million as of September 30, 2025, down from $79.4 million at December 31, 2024.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eApplied Therapeutics, Inc. (APLT) - VRIO Analysis: \u003cstrong\u003e3. Govorestat’s Potential in Classic Galactosemia\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue: Addresses a high unmet need in a genetically defined population, though currently facing regulatory headwinds (CRL received in 2024).\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eClassic Galactosemia is a progressive and debilitating disease with \u003cstrong\u003eno existing treatment options\u003c\/strong\u003e. The patient population is estimated at approximately \u003cstrong\u003e3,300 patients\u003c\/strong\u003e in the U.S. and approximately \u003cstrong\u003e4,400 patients\u003c\/strong\u003e in the E.U. Newborn screening for Galactosemia is mandatory in the U.S. and most E.U. countries. Govorestat demonstrated the ability to reduce plasma galactitol levels, a toxic metabolite responsible for tissue damage.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. Patient Population\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e3,300\u003c\/strong\u003e patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eE.U. Patient Population\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e4,400\u003c\/strong\u003e patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew U.S. Births Per Year\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e80-100\u003c\/strong\u003e new births per year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew E.U. Births Per Year\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e120\u003c\/strong\u003e new births per year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA Action Date (Original PDUFA)\u003c\/td\u003e\n\u003ctd\u003eNovember 28, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCRL Issuance Date\u003c\/td\u003e\n\u003ctd\u003eNovember 27, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity: Moderate; other ARIs exist, but this compound’s specific profile for this indication is unique.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGovorestat is a novel, \u003cstrong\u003ecentral nervous system (CNS)-penetrant Aldose Reductase Inhibitor (ARI)\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGovorestat was previously granted \u003cstrong\u003ePediatric Rare Disease designation\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePotential for a \u003cstrong\u003ePriority Review Voucher (PRV)\u003c\/strong\u003e upon approval.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability: High, due to the specific clinical data generated for this indication.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe New Drug Application (NDA) submission was supported by data from multiple studies:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePhase 3 registrational \u003cstrong\u003eACTION-Galactosemia Kids study\u003c\/strong\u003e in children aged \u003cstrong\u003e2-17\u003c\/strong\u003e with Galactosemia.\u003c\/li\u003e\n\u003cli\u003eThe ACTION-Galactosemia Kids study evaluated govorestat versus placebo in \u003cstrong\u003e47 children\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePhase 1\/2 \u003cstrong\u003eACTION-Galactosemia study\u003c\/strong\u003e in adult patients.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization: Management has a Q4 2025 meeting scheduled with the FDA to discuss the path forward, showing commitment.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe Company has been granted a meeting with the FDA in the \u003cstrong\u003efourth quarter of 2025\u003c\/strong\u003e to align on the regulatory path forward following the Complete Response Letter.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Metric\u003c\/th\u003e\n\u003cth\u003eReported Value\u003c\/th\u003e\n\u003cth\u003eDate\/Period\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Short-Term Investments\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$50.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMarch 31, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Capitalization\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$30.7 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eEarly December 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStock Price (Recent)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.21\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEarly December 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Temporary; value is currently capped by the unresolved regulatory status.\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eApplied Therapeutics, Inc. (APLT) - VRIO Analysis: \u003cstrong\u003e4. Advanced Crystallography Expertise for ARI Optimization\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides a deep, unique understanding of the Aldose Reductase enzyme’s active site structure, differentiating their ARIs.\u003c\/p\u003e\n\u003cp\u003eThis expertise underpins the development of novel Aldose Reductase Inhibitors (ARIs) designed for improved binding affinity and specificity, aiming for higher inhibitory activity and less off-target activity. The ARI franchise includes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGovorestat (AT-007) for CNS rare metabolic diseases (Galactosemia, SORD Deficiency, PMM2-CDG).\u003c\/li\u003e\n\u003cli\u003eAT-001 for Diabetic Cardiomyopathy (DbCM).\u003c\/li\u003e\n\u003cli\u003eAT-003 for Diabetic Retinopathy (DR).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High; this specific, deep structural knowledge applied to this enzyme class is not widely held.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High; this is tacit knowledge built over time, not easily bought or reverse-engineered.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e This expertise is embedded in the R\u0026amp;D process, which is currently lean, focusing resources here. The financial commitment to this core scientific capital is demonstrated by the allocation of Research and Development expenses:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expense Category\u003c\/td\u003e\n\u003ctd\u003eYear Ended Dec 31, 2024 (in thousands)\u003c\/td\u003e\n\u003ctd\u003eYear Ended Dec 31, 2023 (in thousands)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAT-001 (ARI Program)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4,600\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$19,540\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAT-007 (ARI\/Govorestat)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$29,360\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$24,319\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Product Pipeline R\u0026amp;D Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$33,960\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$43,859\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Research and Development Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$48,744\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$53,905\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe R\u0026amp;D expenses for the three months ended September 30, 2024, were \u003cstrong\u003e$14.8 million\u003c\/strong\u003e, compared to \u003cstrong\u003e$10.8 million\u003c\/strong\u003e for the three months ended September 30, 2023. For the three months ended September 30, 2025, R\u0026amp;D expenses were \u003cstrong\u003e$9.6 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, as it represents deep, specialized scientific capital.\u003c\/p\u003e\n\u003cp\u003eThe investment in the ARI program, including the foundational crystallography work, is a significant component of the company's overall R\u0026amp;D spend, which was \u003cstrong\u003e$48.7 million\u003c\/strong\u003e for the year ended December 31, 2024. The AT-001 Phase I\/II clinical trial evaluated approximately \u003cstrong\u003e120 patients\u003c\/strong\u003e with type II diabetes.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eApplied Therapeutics, Inc. (APLT) - VRIO Analysis: \u003cstrong\u003e5. PMM2-CDG Program and Expanded Access\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides pipeline depth beyond the lead candidate, targeting a severe disease with new data published in late 2025.\u003c\/p\u003e\n\u003cp\u003ePMM2-CDG is described as a severe disease with a high mortality rate in pediatric patients. Clinical data from an ongoing single-patient investigator-initiated trial evaluating govorestat for PMM2-CDG was published in the Journal of Inherited Metabolic Disease (JIMD) and presented at the 2025 ASHG Annual Meeting in October 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High; few companies are targeting PMM2-CDG with a small molecule approach.\u003c\/p\u003e\n\u003cp\u003eThe program is supported by the use of govorestat, a small molecule Aldose Reductase Inhibitor (ARI). The clinical evidence presented stems from a single-patient trial conducted under an investigator-led single-patient expanded access investigational new drug (IND) application.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High; the clinical data and Expanded Access program are company-specific achievements.\u003c\/p\u003e\n\u003cp\u003eThe specific data presentation in October 2025 is a direct result of the company’s execution on this specific program. The program has secured specific regulatory statuses from the FDA for govorestat (AT-007) in PMM2-CDG.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The company is actively supporting investigator-initiated trials and data presentation, showing resource allocation.\u003c\/p\u003e\n\u003cp\u003eFinancial metrics from Q3 2025 reflect ongoing resource commitment to the pipeline:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eAmount (in thousands)\u003c\/th\u003e\n\u003cth\u003ePeriod End Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch and Development Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$9,600\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneral and Administrative Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8,200\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eThree Months Ended September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$11,945\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe company has 250,000,000 shares authorized as of September 30, 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, due to the early-mover advantage in a niche, high-need orphan indication.\u003c\/p\u003e\n\u003cp\u003eThe competitive positioning is reinforced by specific regulatory acknowledgments:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eOrphan Drug Designation from the FDA for PMM2-CDG.\u003c\/li\u003e\n\u003cli\u003eRare Pediatric Disease designation from the FDA for PMM2-CDG.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eInitial in vitro data demonstrated that AT-007 treatment increases phosphomannomutase 2 activity in fibroblast cell lines derived from PMM2-CDG patients.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eApplied Therapeutics, Inc. (APLT) - VRIO Analysis: \u003cstrong\u003e6. Regulatory Engagement and Dialogue with the FDA\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The ability to secure and conduct constructive meetings with the FDA on complex rare disease pathways is crucial for approval timelines.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eConstructive dialogue is evidenced by specific scheduled and completed interactions concerning govorestat across multiple rare indications.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eIndication\u003c\/th\u003e\n\u003cth\u003eMeeting Status\/Type\u003c\/th\u003e\n\u003cth\u003eAnnounced Date\/Period\u003c\/th\u003e\n\u003cth\u003eRelevant Target Date\/Outcome\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMT-SORD\u003c\/td\u003e\n\u003ctd\u003eCompleted Meeting to discuss potential NDA submission\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eQ3 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAwaiting official meeting minutes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClassic Galactosemia\u003c\/td\u003e\n\u003ctd\u003eMeeting scheduled to discuss follow-up to CRL\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eQ4 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReceived \u003cstrong\u003eComplete Response Letter (CRL)\u003c\/strong\u003e on \u003cstrong\u003eNovember 27, 2024\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; many firms have regulatory teams, but success in securing key meetings post-CRL is a specific skill.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe focus on specific, low-prevalence rare diseases requires engagement tailored to unique regulatory pathways.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCMT-SORD U.S. Patient Population: Approximately \u003cstrong\u003e3,300 patients\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eCMT-SORD EU Patient Population: Approximately \u003cstrong\u003e4,000 patients\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eGovorestat holds Orphan Drug designation from the FDA for Galactosemia, PMM2-CDG, and SORD deficiency\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Temporary; success depends on the specific data package and the current FDA climate.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe ability to navigate post-adverse action dialogue is time-sensitive and data-dependent.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eInitial NDA for Classic Galactosemia received a \u003cstrong\u003eCRL\u003c\/strong\u003e on \u003cstrong\u003eNovember 27, 2024\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eFollowing the CRL, the company received a \u003cstrong\u003eWarning Letter\u003c\/strong\u003e on \u003cstrong\u003eDecember 2, 2024\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eThe company is actively requesting follow-up meetings to address deficiencies cited in the \u003cstrong\u003eCRL\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The team is clearly organized around regulatory milestones, evidenced by the Q4 2025 meeting schedules.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eResource allocation and operational focus are directed toward achieving defined regulatory milestones.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Metric (as of 6\/30\/2025)\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003cth\u003eContextual Period\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$30.4M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDown from \u003cstrong\u003e$79.4M\u003c\/strong\u003e at \u003cstrong\u003eDecember 31, 2024\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$21.3M\u003c\/strong\u003e (\u003cstrong\u003e$0.15 per share\u003c\/strong\u003e)\u003c\/td\u003e\n\u003ctd\u003eFor the three months ended \u003cstrong\u003eJune 30, 2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; it’s an ongoing process, not a static asset.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe advantage is maintained only through the successful execution of the next scheduled regulatory step.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNext critical step for CMT-SORD: Awaiting official minutes from the \u003cstrong\u003eQ3 2025\u003c\/strong\u003e FDA meeting to determine next steps for potential NDA submission\u003c\/li\u003e\n\u003cli\u003eNext critical step for Classic Galactosemia: The follow-up meeting scheduled for \u003cstrong\u003eQ4 2025\u003c\/strong\u003e to address the \u003cstrong\u003eCRL\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eApplied Therapeutics, Inc. (APLT) - VRIO Analysis: \u003cstrong\u003e7. The Urine Sorbitol Assay Diagnostic Tool\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eRemoves a barrier to diagnosis and care management for patients by offering the test at \u003cstrong\u003eno cost\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eModerate; companion diagnostics are common, but one offered free to remove patient friction is less so.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLow; a simple assay is relatively easy for a competitor to develop if they gain market entry.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIt’s a supportive resource that aids patient identification for their pipeline, showing patient-centric organization.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAids identification for patients with Charcot-Marie-Tooth Sorbitol Dehydrogenase Deficiency (CMT-SORD).\u003c\/li\u003e\n\u003cli\u003eThe program is intended to support health care providers in identifying suspected cases through urine-based sorbitol measurement.\u003c\/li\u003e\n\u003cli\u003eThe assay is part of a sponsored testing program offered through Mayo Clinic Laboratories in collaboration with Applied Therapeutics.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTemporary; it’s a supporting tool, not a primary revenue driver.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eContext\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAssay Launch Month\u003c\/td\u003e\n\u003ctd\u003eJuly\u003c\/td\u003e\n\u003ctd\u003e2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCost to Patient\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePer test\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ2 2025 Net Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$21.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFor the three months ended June 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$30.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of June 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eApplied Therapeutics, Inc. (APLT) - VRIO Analysis: \u003cstrong\u003e8. Strategic Flexibility and Board Mandate for Alternatives\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003c\/p\u003e\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eThe Board exploring mergers, licensing, or partnerships provides a necessary off-ramp or funding mechanism given the low cash position of \u003cstrong\u003e$11.9 million\u003c\/strong\u003e as of \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eModerate; many companies explore this, but the mandate itself signals a clear, urgent organizational response.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eLow; the specific terms and timing of any deal are unique to Applied Therapeutics.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eThe exploration of strategic alternatives is a direct, high-level organizational response to the Q3 2025 cash balance of only \u003cstrong\u003e$11.9 million\u003c\/strong\u003e. This is coupled with organizational restructuring:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eWorkforce reduction of \u003cstrong\u003e46%\u003c\/strong\u003e planned by the end of \u003cstrong\u003eQ4 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eImplementation of additional cost-containment and cash conservation measures.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe strategic review options being evaluated include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMergers\u003c\/li\u003e\n\u003cli\u003eAcquisitions\u003c\/li\u003e\n\u003cli\u003ePartnerships\u003c\/li\u003e\n\u003cli\u003eJoint ventures\u003c\/li\u003e\n\u003cli\u003eLicensing arrangements\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003c\/p\u003e\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eTemporary; this is a reactive measure to a financial constraint, not a proactive source of advantage.\u003c\/p\u003e\n\u003cp\u003eFinancial context underpinning the mandate:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eDate\/Period\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$11.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents (Prior)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$79.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDecember 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Debt\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.50 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest available\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Cash Position\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$9.45 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest available\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEBITDA (Last 12 Months)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-$99.61 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLast 12 Months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Capitalization\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$30.7 million\u003c\/strong\u003e to \u003cstrong\u003e$41 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eNovember\/December 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eApplied Therapeutics, Inc. (APLT) - VRIO Analysis: \u003cstrong\u003e9. Out-licensing Agreement for Non-Core Asset (AT-001)\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eThe out-licensing agreement for AT-001 with Biossil, Inc. was executed on \u003cstrong\u003eJuly 31, 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe agreement generated near-term cash and potential future consideration from the non-core asset AT-001, an investigational, novel Aldose Reductase Inhibitor for Diabetic Cardiomyopathy.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eDeal Component\u003c\/th\u003e\n\u003cth\u003eAT-001 Out-license to Biossil, Inc. (July 2025)\u003c\/th\u003e\n\u003cth\u003eAdvanz Pharma Agreement (Prior Deal)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfront Payment\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eEUR 10.0M\u003c\/strong\u003e (approximately \u003cstrong\u003e$10.7M\u003c\/strong\u003e)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePotential Milestones\u003c\/td\u003e\n\u003ctd\u003eEligible for future milestone payments\u003c\/td\u003e\n\u003ctd\u003ePotential \u003cstrong\u003eEUR 134M\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalties\u003c\/td\u003e\n\u003ctd\u003eEligible for future royalties\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e20%\u003c\/strong\u003e on net sales in the Territory\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eOut-licensing of non-core assets is a standard practice within the biopharmaceutical industry.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe specific deal terms negotiated with Biossil, Inc. are unique to this transaction.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe transaction demonstrates an organizational capability to monetize non-core Intellectual Property to supplement operations.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash and cash equivalents as of \u003cstrong\u003eJune 30, 2025\u003c\/strong\u003e: \u003cstrong\u003e$30.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash and cash equivalents as of \u003cstrong\u003eDecember 31, 2024\u003c\/strong\u003e: \u003cstrong\u003e$79.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet loss for the three months ended \u003cstrong\u003eJune 30, 2025\u003c\/strong\u003e: \u003cstrong\u003e$21.3 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eOperating cash used for the six months ended \u003cstrong\u003eJune 30, 2025\u003c\/strong\u003e: \u003cstrong\u003e$49.0 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eShares of common stock outstanding as of \u003cstrong\u003eAugust 12, 2025\u003c\/strong\u003e: \u003cstrong\u003e144,012,125\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThis event is classified as a transactional event, not indicative of a sustained capability conferring competitive advantage.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eFinance\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eDraft 13-week cash view by Friday.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516134842517,"sku":"aplt-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/aplt-vrio-analysis.png?v=1740147202","url":"https:\/\/dcf-model.com\/pt\/products\/aplt-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}